Previous 10 | Next 10 |
With its share price down 56% in the past 12 months, STAAR Surgical 's (NASDAQ: STAA) stock has clearly seen better days. Judging by its collapse, it'd be reasonable to assume the implantable lens company is facing major headwinds -- but it isn't. In fact, there's not much standing ...
STAAR Surgical (NASDAQ: STAA) , which specializes in implantable lenses for the eye, saw its shares drop 12% this week, according to data from S&P Global Market Intelligence . The stock is down more than 58% so far this year and has a 52-week high of $163.08 and a low of $54...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced that it will release financial results for the first quarter ended April 1, 2022 on Wednesday, May 4, 2022 ...
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Small cap growth stocks entered bear market territory dur...
STAAR has a 20% 5-year average of year over year revenue growth and high gross margins of 77.5% for 2021 and 72.4% for 2020. Used to treat hyperopia, myopia, and astigmatism, their product has been implanted in more than 1M eyes spanning across 75 plus countries. On the 28th of Ma...
STAAR Surgical (NASDAQ:STAA) announced the first implants of its EVO Visian Implantable Collamer lens (EVO ICL) in the U.S. for the correction of myopia and myopia with astigmatism. The implantable lens were approved by the U.S. Food and Drug Administration just over a week ago. The...
Announces Program of Meetings and Presentations at Upcoming ASCRS Annual Meeting STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of implantable lenses and companion delivery systems for the eye, today announced the first implants of the ...
STAAR Surgical (NASDAQ: STAA) stood out as one of the top performers in the healthcare sector on Monday. The stock was up 10.1% as of 3:48 p.m. ET after the company announced that the U.S. Food and Drug Administration (FDA) has approved the EVO/EVO+ Visian Implantable Collamer Lens ...
A major C-Suite shakeup has sent shares of EV charging company Volta (NYSE:VLTA) sharply lower in Monday's intraday trading. The stock also suffered an analyst's downgrade. A bearish analyst comment also put pressure on Beyond Meat (BYND), with Piper Sandler raising competition concerns. Look...
Shares of STAAR Surgical (NASDAQ: STAA) were surging 10.9% higher as of 11:17 a.m. ET after rising as much as 19.4% earlier in the day. The big gain came after the company announced that the U.S. Food and Drug Administration (FDA) approved the EVO/EVO+ Visian Implantable Collamer Le...
News, Short Squeeze, Breakout and More Instantly...
STAAR Surgical Company Company Name:
STAA Stock Symbol:
NASDAQ Market:
STAAR Surgical Company Website:
2024-07-14 17:28:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
STAAR Surgical Company (NASDAQ: STAA), a leading developer, manufacturer and marketer of the EVO family of Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism and presbyopia, invites investors and the general public to listen to a webcast fireside chat with Patrick F. Will...
2024-05-24 07:48:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...